According to reports, a new drug has been found to prevent a migraine and it has also been approved by European health officials. The drug named Erenumab will now be examined by English and Scottish health agencies to determine if it is liable to be used by officials of National Health Service.
Manufacturers of Erenumab, Novartis said, “The drug can be privately bought by patients who suffer from four migraines in a month after its license is approved by European Medicines Agency. Also known as Aimovig, the drug was intended to block the calcitonin gene-related peptide receptor that is thought to be instrumental in migraine activation.”
The manufacturers said, “Erenumab is the first and the only licensed drug designed primarily to prevent a migraine. It can be administered without much help with an auto-injector pen once a month.”
Haseeb Ahmad, managing director for UK and Ireland of Novartis Pharmaceuticals said, “Erenumab is the first and only licensed treatment specifically designed to prevent a migraine, demonstrating our commitment to developing innovative therapies for people living with some of the most debilitating conditions.”
Wendy Thomas, chief executive of the Migraine Trust, said, “Migraine is incredibly painful and has symptoms that include vomiting and visual disturbance, so getting it frequently can literally ruin lives. That is why it is important that it becomes available to patients as soon as possible.”
